lilly retatrutide trial Eli just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Eli Lilly stock jumps on

If you microdose retatrutide and lose the glucagon component, you might go from 24% weight loss to 15% weight loss, essentially converting your triple agonist into a less efficient version of what you could get from semaglutide alone

Novo Nordisk and Lilly are both filing for oral semaglutide and orforglipron

The manufacturer also offers a Home Delivery Program at $99/month or less with free shipping

It is the first of these medications to interact with two hormones in the body, which is why researchers believe it manages blood sugar levels better than previous medicines and helps people lose more weight

It is essentially a paralysis of the bowel